SSI Diagnostica, a portfolio company of private investment firm Adelis Equity, announced that it has acquired Gulf Coast Scientific.
Gulf Coast Scientific develops, manufactures and distributes non-invasive diagnostic solutions for the detection of Helicobacter Pylori. Founded in 1996, the company has a record of FDA-approved product ranges composed of various samplers, port analyzers and test tubes. The company has a strong position in the American as well as international markets.
Based in Denmark, SSI Diagnostica is a global developer and manufacturer of in vitro diagnostic solutions for infectious diseases focused on gastric, respiratory and bloodborne conditions.
The acquisition of Gulf Coast Scientific strengthens SSI Diagnostica’s gastrointestinal disease testing portfolio and expands its footprint in the U.S. clinical diagnostic market. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 38th Laboratories, MRI and Dialysis acquisition of 2025, and the 18th in the diagnostic specialty. There were 63 diagnostic deals announced in both 2024 and 2023.
Additionally, this marks the first healthcare deal announced in Denmark during 2025. There were nine Denmark-based deals announced in 2024, and nine announced in 2023.
